Bronchoalveolar Cell Lung Cancer Completed Phase 2 Trials for Gefitinib (DB00317)

IndicationStatusPhase
DBCOND0028477 (Bronchoalveolar Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00029003Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT00040794Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung CancerTreatment